EGAD00001000366 |
WGBS data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years. |
Illumina HiSeq 2000 |
52 |
EGAD00001000884 |
In order to elucidate whether newly acquired genetic alterations during serial transplantation of patient derived primary pancreatic cancer cultures contribute to the observed clonal dynamics in vivo, all coding genes of two patient derived primary cultures and derived genetically marked serial xenografts (1°/2°/3°) were sequenced. |
Illumina HiSeq 2000 |
10 |
EGAD00001000992 |
HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving events caused by differential SIX1 binding of the SIX1 Q177R mutatns |
Illumina HiSeq 2500 |
3 |
EGAD00001000993 |
HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving gene expression events |
Illumina HiSeq 2000 |
40 |
EGAD00001000994 |
HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving chromosomal aberrations |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
56 |
EGAD00001000995 |
HIPO blastemal Wilms (nephroblastoma) characterisation of tumor driving DNA alterations |
Illumina HiSeq 2000 |
112 |
EGAD00001000997 |
Whole-exome sequencing of a chronic lymphocytic leukemia (CLL) developed during vemurafenib treatment of a patient with malignant melanoma. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation. DNA was extracted from highly purified (>97%) CD19+CD5+ cells obtained from the patient while being under BRAF inhibition versus CD14+ germline control cells (>90% purity). No alterations that could be linked to aberrant RAS activity or paradoxical RAF/MEK/ERK signaling could be identified in the CLL, which shows characteristic copy number alterations. |
Illumina HiSeq 2500 |
2 |
EGAD00001001384 |
Mutations that activate the RAF-MEK-ERK signaling pathway, in particular BRAFV600E, occur in many cancers, and mutant BRAF-selective inhibitors have clinical activity in these diseases. Activating BRAF alleles are usually considered to be mutually exclusive with mutant RAS, whereas inactivating mutations in the D594F595G596 motif of the BRAF activation segment can coexist with oncogenic RAS and cooperate via paradoxical MEK/ERK activation. We determined the functional consequences of a largely uncharacterized BRAF mutation, F595L, which was detected along with an HRASQ61R allele by clinical exome sequencing in a patient with histiocytic sarcoma and also occurs in epithelial cancers, melanoma, and neuroblastoma, and investigated its interaction with mutant RAS. We demonstrate that, unlike previously described DFG motif mutants, BRAFF595L is a gain-of-function variant with intermediate activity towards MEK that does not act paradoxically, but nevertheless cooperates with mutant RAS to promote oncogenic signaling. Of immediate clinical relevance, BRAFF595L shows divergent responses to different mutant BRAF-selective inhibitors, whereas signaling driven by BRAFF595L with and without mutant RAS is efficiently blocked by pan-RAF and MEK inhibitors. Mutation data from primary patient samples and cell lines show that BRAFF595L, as well as other BRAF mutations with intermediate activity, frequently coincide with mutant RAS in a broad spectrum of cancers. These data define a novel class of activating BRAF mutations that cooperate with oncogenic RAS in a non-paradoxical fashion to achieve an optimal level of MEK-ERK signaling, extend the spectrum of patients with systemic histiocytic disorders and other malignancies who are candidates for therapeutic blockade of the RAF-MEK-ERK pathway, and underscore the value of comprehensive genetic profiling for understanding the signaling requirements of individual cancers. |
Illumina HiSeq 2500 |
2 |
EGAD00001001444 |
Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants and young children. Although the prognosis of ATRT patients is poor, some patients respond very well to current treatments, suggesting inter-tumor molecular heterogeneity. To investigate this further, we genetically and epigenetically analyzed a large cohort of ATRTs (n = 170). Three distinct molecular subgroups of ATRTs, associated with differences in demographics, tumor location and type of SMARCB1 alterations, were identified using DNA-methylation or gene expression analyses. Whole genome DNA- and RNA-sequencing found no other recurrent mutations explaining the differences between subgroups. However, whole genome bisulfite-sequencing and H3K27Ac ChIP-sequencing of primary tumors revealed clear differences in methylation patterns and enhancer landscapes, leading to the identification of subgroup-specific regulatory networks. |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
55 |
EGAD00001002011 |
RNA sequencing data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years. |
|
64 |
EGAD00001002012 |
ChIPseq data of whole blood samples from smoking and non-smoking mothers and their children at gestation/birth and follow-up years. |
|
16 |
EGAD00001002055 |
Whole exome sequencing from matched tumor-control samples of 121 primary lymphoma samples. Sequencing was performed on Illumina HiSeq2000. The dataset contains FASTQ files. |
Illumina HiSeq 2000 |
242 |
EGAD00001002056 |
Paired-end RNA sequencing using total RNA from 136 primary lymphoma samples. Sequencing was performed on the Illumina HiSeq2000 with 300bp insert size. The dataset contains FASTQ files. |
Illumina HiSeq 2000 |
136 |
EGAD00001002135 |
ChIPseq data of Atypical teratoid/rhabdoid tumors (ATRT) |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
15 |
EGAD00001002136 |
RNA sequencing data of Atypical teratoid/rhabdoid tumors (ATRT) |
Illumina HiSeq 2000 |
25 |
EGAD00001002137 |
WGBS data of Atypical teratoid/rhabdoid tumors (ATRT) |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
15 |
EGAD00001002138 |
WGS data of Atypical teratoid/rhabdoid tumors (ATRT) |
Illumina HiSeq 2000 |
36 |
EGAD00001002159 |
Exome Seq for Study EGAS00001001844 |
Illumina HiSeq 2000 |
2 |
EGAD00001002160 |
Exome Seq for EGAS00001001845 |
Illumina HiSeq 2500 |
2 |
EGAD00001002161 |
Transcriptome from EGAS00001001845 |
Illumina HiSeq 2500 |
1 |
EGAD00001002162 |
Exome Seq from EGAS00001001846 |
Illumina HiSeq 2500 |
2 |
EGAD00001002163 |
Transcriptome from EGAS00001001846 |
Illumina HiSeq 2500 |
1 |
EGAD00001002164 |
Exome from EGA00001001848 |
Illumina HiSeq 2000 |
2 |
EGAD00001002166 |
Exome from EGAS00001001861 |
Illumina HiSeq 2000 |
17 |
EGAD00001002528 |
WGS from EGAS00001001857 |
Illumina HiSeq 2000 |
18 |
EGAD00001003325 |
Exome from EGAS00001002441 |
Illumina HiSeq 2500 |
2 |
EGAD00001003408 |
Chip-Seq sequencing data of Atypical teratoid/rhabdoid tumors (ATRT) |
Illumina HiSeq 2000 |
19 |
EGAD00001003421 |
Sequence data of 28 Samples (19 chronic lymphocytic leukemia, 9 control)
Including RNA-Seq and ChIP-Seq of following histone modifications: H3, H3K4me1, H3K4me3, H3K9ac, H3K9me3, H3K27ac, H3K27me3, H3K36me3
Project see: http://www.cancerepisys.org/ |
|
28 |
EGAD00001003827 |
The data set contains bam files aligned using bwa-0.7.8 mem -t 8 -R. |
HiSeq X Ten |
4 |
EGAD00001003828 |
This dataset contains paired fastq files for LMS tumor samples |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
37 |
EGAD00001003829 |
The data set contains paired end fastq files for whole exome sequencing data for Leiomyosarcoma tumor and control samples |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
96 |
EGAD00001003965 |
Whole genome sequencing of Control (blood), Tumor and metastasis triplets for 12 samples. |
Illumina HiSeq 2000 |
36 |
EGAD00001004068 |
Whole-genome, whole-exome and transcriptome sequencing of pancreatic ductal adenocarcinomas from young adults reveals recurrent NRG1-fusions in KRAS wild-type tumors. |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
36 |
EGAD00001004563 |
This dataset contains whole genome sequencing data from 21 primary and relapsed IDH-wt glioblastomas and matched blood controls. Tumors were sequenced at a target coverage of 150x, blood controls at 80x. |
HiSeq X Ten |
63 |
EGAD00001004564 |
This dataset contains strand-specific RNA sequencing data from 16 primary/relapsed sample pairs of IDH-wt glioblastomas |
Illumina HiSeq 2000 |
32 |
EGAD00001004565 |
This dataset contains gene panel sequencing data from 43 sample pairs of primary and relapsed IDH-wt glioblastomas. The gene panel covers 50 glioma-associated genes. 14 of the sequenced sample pairs were sequenced with whole genome sequencing also and are accessible under EGAD00001004563. |
Ion Torrent Proton |
86 |
EGAD00001004825 |
Case series of the rare tumor entity chordoma. 9 cases sequenced with Whole Exome Sequencing (WES) and 2 cases sequenced with Whole Genome Sequencing (WGS) were recruited from the personalized oncology program NCT-MASTER/DKTK-MASTER at the German Cancer Research Center. One of the WES patients was re-sequenced at a later time point when he relapsed, this resequencing was done by WGS. Therefore there are 11 patients, one of which with two samples, all of which were sequenced with matched normal controls, amounting to a total number of 24 NGS samples. |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
24 |
EGAD00001005061 |
Bam files for 124 samples (62 tumor vs blood pairs); Whole Genome Sequencing performed on Illumina HiSeq X Ten |
HiSeq X Ten |
124 |
EGAD00001005069 |
Whole genome and transcriptome sequencing of a pancreatic tumor harboring a RASGRP1 gene fusion |
HiSeq X Ten,Illumina HiSeq 4000 |
2 |
EGAD00001005113 |
50 samples of 16 individuals with Gastrointestinal Tumor. Patients were sequenced in various combinations of WGS, Exome and RNA sequencing. |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
50 |
EGAD00001005249 |
Exome and RNA sequencing data for EGAS00001003776 - one female patient with neurofibroma/schwannoma hybrid nerve sheath tumor (N/S HNST) |
Illumina HiSeq 2500 |
2 |
EGAD00001005492 |
Content: 60 GB patient tumours and 4 normal brain samples combined in pairs by region (x2=8 total input samples).
RNAseq: 1 lane per sample, total strand-specific rRNA-depleted (normal samples were combined = 2 lanes/samples per brain region).
WGBS: 2 lanes per sample (normal samples were combined = 2 lanes/samples per brain region).
ChIPseq (histone mark): a subset of 20 GB samples were profiled. For the same modification were multiplexed and sequenced on 4 lanes each (H3K27ac, H3K4me1) or a single lane (all others).
WGS: used as matching input control for the 20 ChIPseq samples.
Data type and technology:
RNA-seq: PE 100bp sequenced on HiSeq2000.
WGBS: PE 100bp sequenced on HiSeq2000/4000.
ChIPseq: SE 50bp sequenced on HiSeq2000/4000.
WGS: PE 150bp sequenced on HiSeq X. |
|
172 |
EGAD00001005493 |
Content: 2 GB RTK I cell lines (LN229, ZH487) in two conditions (NT control and shSOX10).
RNAseq: single replicates per condition, polyA+ RNA sequencing, SE.
ATACseq: biological replicates per condition, SE.
ChIPseq (histone H3 modifications, LN229 only): all marks for each condition were pooled and sequenced on two lanes for each pool.
ChIPseq (BRD4 and SOX10): SOX10 libraries were sequenced on single lanes. BRD4 samples were multiplexed and sequenced in two lanes.
ChIPseq input samples are also included.
Data type and technology:
RNAseq: SE 50bp sequenced on HiSeq2000/4000.
ATACseq: SE 50bp sequenced on HiSeq2000/4000.
ChIPseq: SE 50bp sequenced on HiSeq2000/4000. |
|
6 |
EGAD00001005938 |
This dataset contains 3 pairs of exomes, germline (from whole blood) and patient-derived xenograft (PDX), from human pancreatic durctal adenocarcinoma patients. The data is referred to in the publication: "Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy" (Nature Communications, 2020)
Abstract: Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression of immune cell function by cytostatic drugs may limit therapeutic efficacy. Here we show that targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) does not impair dendritic cell-mediated T-cell priming and activation. Accordingly, combining MEK inhibitors (MEKi) with agonist antibodies (Abs) targeting the immunostimulatory CD40 receptor resulted in potent synergistic anti-tumor efficacy. Detailed analysis of the mechanism of action of MEKi GDC-0623 by means of flow cytometric analysis of the tumor immune infiltrate and whole tumor transcriptomics showed that, in addition to its cytostatic impact on tumor cells, this drug exerts multiple pro-immunogenic effects, including the suppression of M2-type macrophages, myeloid derived suppressor cells and CD4+ T-regulatory cells. In addition, MEKi was found to induce tumor-cell intrinsic interferon signaling, which contributed to antigen presentation by tumor cells. Finally, the tumoridical impact of MEKi involves the activation of multiple pro-inflammatory pathways involved in immune cell effector function in the tumor microenvironment. Our data therefore indicate that the combination of MEK inhibition with agonist anti-CD40 Ab is a promising therapeutic concept, especially for the treatment of mutant Kras-driven tumors such as pancreatic ductal adenocarcinoma. |
Illumina HiSeq 2500 |
6 |
EGAD00001005965 |
Single-cell ATAC-seq data for 5 CLL samples (2 controls, 3 tumor) of the CancerEpiSys-PRECiSe project. |
Illumina HiSeq 2000 |
5 |
EGAD00001005966 |
Tagged-WGBS for 3 Naive B Cell samples of the CancerEpiSys-PRECiSe project. |
Illumina HiSeq 2000 |
3 |
EGAD00001005967 |
ATAC-seq data for 26 CLL samples (7 controls, 19 tumor) of the CancerEpiSys-PRECiSe project. |
Illumina HiSeq 2000,Illumina HiSeq 4000 |
26 |
EGAD00001005968 |
long RNA data for 27 CLL samples (8 controls, 19 tumor) of the CancerEpiSys-PRECiSe project. |
Illumina HiSeq 2000 |
27 |
EGAD00001005969 |
ChIPseq data for 31 CLL samples (12 controls, 19 tumor) of the CancerEpiSys-PRECiSe project; containing histone H3, histone modifications and transcription factor binding sites (CTCF, EBF1). |
Illumina HiSeq 2000,NextSeq 550 |
31 |
EGAD00001005970 |
WGBS data for 75 paired fastq, spread over 31 samples (4 healthy T-cell, 7 healthy B-cell, 20 B-cell CLL tumors) of the CancerEpiSys-PRECiSe project. |
Illumina HiSeq 2000 |
31 |
EGAD00001006005 |
liver cancer paired with normal controls, viral and non-viral origin |
|
108 |
EGAD00001006014 |
NA |
HiSeq X Ten,Illumina HiSeq 4000 |
2 |
EGAD00001006016 |
NA |
HiSeq X Ten,Illumina HiSeq 2000 |
12 |
EGAD00001006023 |
NA |
HiSeq X Ten,Illumina HiSeq 4000 |
2 |
EGAD00001006057 |
paired WGS sequencing of nodal B-cell lymphoma, one tumor and one control, one patient (H021). Sequencing on Hiseq XTen with TruSeq Nano library preparation kit. |
HiSeq X Ten |
2 |
EGAD00001006058 |
paired WGS data of one tumor of one patient with nodal B-cell lymphoma. Tumor cells were sorted according to CD48 expression in a high and low fraction. Library preparation with TruSeq Nano and sequencing on Hiseq XTen. |
HiSeq X Ten |
2 |
EGAD00001006059 |
Tumors and control of nodal B-cell lymphoma of one patient. WES sequencing on Illumina HiSeq 4000 with Agilent SureSelect V5+UTRs. Bam files were aligned with bwa mem to hg19. |
Illumina HiSeq 4000 |
5 |
EGAD00001006060 |
paired EXOME sequencing on Illumina HiSeq 4000 using Agilent SureSelect V6 of one tumor sample of one patient with B-cell lymphoma. The bam-file was mapped to the hg19 genome. |
Illumina HiSeq 4000 |
1 |
EGAD00001006184 |
linking MASTER H021-Cohort to EGAS0001004157 |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
10 |
EGAD00001006189 |
Paired WGS and RNA-Seq data of patients with multiple myeloma (MM) refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs). We performed whole genome and transcriptome sequencing of 39 heavily pretreated RRMM patients with at least double refractoriness revealing complex structural changes and a high mutational load. |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 4000 |
116 |
EGAD00001006243 |
NA |
HiSeq X Ten |
2 |
EGAD00001006263 |
linking 3 samples out of EGAD00001002528 to EGAS0001004517 |
Illumina HiSeq 2000 |
3 |
EGAD00001006264 |
18 samples of RNA-Seq of serially passaged TIC-enriched spheres of colorectal cancer (CRC), sequenced on HiSeq2000 and HiSeq2500 |
Illumina HiSeq 2500 |
8 |
EGAD00001006265 |
WGS data of serially passaged TIC-enriched spheres of colorectal cancer |
HiSeq X Ten |
6 |
EGAD00001006266 |
WES data of serially passaged TIC-enriched spheres of colorectal cancer (CRC) |
Illumina HiSeq 2000,Illumina HiSeq 2500 |
15 |
EGAD00001006297 |
270 samples with ALK-positiv non-small cell lung cancer, targeted sequencing (198 kb panel size) |
|
270 |
EGAD00001006298 |
268 samples with ALK-positiv non-small cell lung cancer, ultra-low coverage whole genome sequencing |
|
268 |
EGAD00001006336 |
Paired whole exome sequencing data of the HIPO head and neck cancer (HNC) (n=83), using Agilent SureSelect V4+UTRs and V6+UTRs with the sequencing platforms HiSeq2000 and HiSeq2500. The reads were aligned to hg19. This is part of project H019. |
|
166 |
EGAD00001006538 |
WGBS data for EGAS00001004660, "Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell-of-origin" |
|
13 |
EGAD00001006539 |
RNA data for EGAS00001004660, "Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell-of-origin" |
|
23 |
EGAD00001006544 |
ATAC-seq data for 2 glioblastoma cell lines (LN229, ZH487), NT and SOX10KD. |
|
2 |
EGAD00001006545 |
Whole genome sequencing data for 20 human glioblastoma patients. |
|
20 |
EGAD00001006546 |
Whole Genome Bisulfite data for human glioblastoma patients, EGAS00001003953. 68 human samples |
|
68 |
EGAD00001006547 |
RNA data for human glioblastoma patients, EGAS00001003953. 64 human samples, 2 cell lines (LN229, ZH487). |
|
66 |
EGAD00001006548 |
ChIPseq data for human glioblastoma patients, EGAS00001003953. Mix of input, H3K27ac, H3K27me1, H3K27me3, H3K36me3, H3K4me1, H3K4me3, H3K9me3 and BRD, 20 human samples, 2 cell lines (LN229, ZH487). |
|
22 |
EGAD00001006613 |
linking 82 samples/82 runs of WES from EGAS00001004338 Umbrella study to EGAS0001004786 study |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
0 |
EGAD00001006614 |
linking 58 samples/58 runs of WGS from EGAS00001004338 Umbrella study to EGAS0001004786 study |
HiSeq X Ten |
0 |
EGAD00001006615 |
linking 55 samples/74 RNA-Seq runs - out of EGAS00001004338 Umbrella study to EGAS0001004786 |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
0 |
EGAD00001006739 |
NA |
HiSeq X Ten |
17 |
EGAD00001006785 |
NA |
Illumina HiSeq 4000 |
9 |
EGAD00001006903 |
This dataset includes 87 scRNA-seq samples of bone marrow aspirates of 20 relapsed/refractory patients generated with the 3´(v2) kit of the 10x Chromium platform. Bone marrow cells have been sorted using CD138 +/- fractions using magnetic beads for plasma cell enrichment and processed independently.
For 14/20 patients multiple treatment timepoints are available that includes samples before treatment and at relapse during treatment. |
Illumina HiSeq 4000 |
87 |
EGAD00001007563 |
We analyzed chromothripsis in 252 human breast cancers from two patient cohorts (149 metastatic breast cancers, 63 untreated primary tumors, 29 local relapses, 11 longitudinal pairs) using whole-genome and whole-exome (paired) sequencing. A lot of the WGS samples were sequenced on Illumina HiSeq X-Ten using Illumina TruSeq Nano DNA. For exome sequencing Agilent_SureSelect_V5+UTRs has been used (sequencing on Hiseq2000, Hiseq2500 and Hiseq4000). For exome sequencing Agilent_SureSelect_V5+UTRs has been used (sequencing on Hiseq2000, Hiseq2500 and Hiseq4000). |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
516 |
EGAD00001007713 |
Paired fastq files ( 12 pairs, WES) of EGFR treated and untreated PDX models of mCRCs of 2 patiens sequenced on Illumina HiSeq 2000, the enrichment kit was Agilent SureSelect V5+UTRs. |
Illumina HiSeq 2000 |
6 |
EGAD00001007817 |
This dataset contains 538 Tumor and Control WGS and WES files for samples already submitted and published in study EGAS00001004276 |
Illumina HiSeq 4000,NextSeq 500 |
400 |
EGAD00001007818 |
Some data was previously submitted data under study number EGAS00001004276. In this new dataset we provide additional WGS and Avenio Surveillance Panel data. We utilized 43 ALK+ NSCLC patients receiving targeted ALK therapy to evaluate ctDNA levels based on matched panel-based targeted next generation sequencing (tNGS) and untargeted shallow whole genome sequencing (sWGS). For the Avenio panel the sequencing was done on Illumina NextSeq 550 paired end 150 bp, for WGS the sequencing was done on Illumina HiSeq 4000, partly with KAPA_Hyper_Prep_Kit. In this dataset there are 132 WGS tumor samples and 134 panel sequencing data of plasma. |
Illumina HiSeq 4000,NextSeq 550 |
266 |
EGAD00001008150 |
Four PAIRED WGS samples, tumor and control, were sequenced on a HiSeq X Ten and the library preparation kit used was Illumina TruSeq Nano DNA. The tumor was multiple myeloma from bone marrow. |
HiSeq X Ten |
4 |
EGAD00001008363 |
two tables containing RNASeq expression values to patients with RNA-Seq data in the study "Comprehensive genomic characterization of refractory multiple myeloma (HIPO_067)". From the bam files gene expression was calculated with the annotation of Gencode.v19. Raw Counts and TPM values are given in one table, the other contains filtered TMM normalized CPM values (genes < 1CPM omitted). |
|
0 |
EGAD00001008638 |
FPKM expression values of the CUP/reference/validation cohort used for tissue-of-origin prediction based on transcriptomic data |
|
0 |
EGAD00001008669 |
Beta values of methylation data of the CUP/reference/validation cohort (H021) used for the validation cohort described in the publication |
|
1 |
EGAD00001008844 |
Rare cancer sequencing data of 23 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
16 |
EGAD00001008845 |
Rare cancer sequencing data of 28 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
22 |
EGAD00001008846 |
Rare cancer sequencing data of 45 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
26 |
EGAD00001008847 |
Rare cancer sequencing data of 95 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
64 |
EGAD00001008848 |
Rare cancer sequencing data of 55 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
44 |
EGAD00001008849 |
Rare cancer sequencing data of 87 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
58 |
EGAD00001008850 |
Rare cancer sequencing data of 59 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
38 |
EGAD00001008851 |
Rare cancer sequencing data of 75 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
49 |
EGAD00001008852 |
Rare cancer sequencing data of 50 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
34 |
EGAD00001008853 |
Rare cancer sequencing data of 44 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
30 |
EGAD00001008854 |
Rare cancer sequencing data of 40 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
26 |
EGAD00001008855 |
Rare cancer sequencing data of 97 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
61 |
EGAD00001008856 |
Rare cancer sequencing data of 48 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
33 |
EGAD00001008857 |
Rare cancer sequencing data of 58 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
40 |
EGAD00001008858 |
Rare cancer sequencing data of 49 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
35 |
EGAD00001008859 |
Rare cancer sequencing data of 243 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
164 |
EGAD00001008860 |
Rare cancer sequencing data of 47 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
41 |
EGAD00001008861 |
Rare cancer sequencing data of 92 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
62 |
EGAD00001008862 |
Rare cancer sequencing data of 145 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
104 |
EGAD00001008863 |
Rare cancer sequencing data of 119 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
76 |
EGAD00001008865 |
Rare cancer sequencing data of 87 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
87 |
EGAD00001008866 |
Rare cancer sequencing data of 48 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
48 |
EGAD00001008867 |
Rare cancer sequencing data of 12 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
12 |
EGAD00001008868 |
Rare cancer sequencing data of 94 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
91 |
EGAD00001008869 |
Rare cancer sequencing data of 46 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
46 |
EGAD00001008870 |
Rare cancer sequencing data of 62 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
59 |
EGAD00001008871 |
Rare cancer sequencing data of 119 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
117 |
EGAD00001008872 |
Rare cancer sequencing data of 54 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
52 |
EGAD00001008873 |
Rare cancer sequencing data of 30 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
30 |
EGAD00001008874 |
Rare cancer sequencing data of 18 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
18 |
EGAD00001008875 |
Rare cancer sequencing data of 64 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
61 |
EGAD00001008876 |
Rare cancer sequencing data of 18 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
12 |
EGAD00001008877 |
Rare cancer sequencing data of 55 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
55 |
EGAD00001008878 |
Rare cancer sequencing data of 38 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
31 |
EGAD00001008879 |
Rare cancer sequencing data of 56 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
54 |
EGAD00001008880 |
Rare cancer sequencing data of 86 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
83 |
EGAD00001008881 |
Rare cancer sequencing data of 49 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
44 |
EGAD00001008882 |
Rare cancer sequencing data of 91 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
78 |
EGAD00001008883 |
Rare cancer sequencing data of 162 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
149 |
EGAD00001008884 |
Rare cancer sequencing data of 83 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
71 |
EGAD00001008885 |
Rare cancer sequencing data of 96 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
89 |
EGAD00001008886 |
Rare cancer sequencing data of 29 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
28 |
EGAD00001008887 |
Rare cancer sequencing data of 66 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
58 |
EGAD00001008888 |
Rare cancer sequencing data of 48 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
41 |
EGAD00001008889 |
Rare cancer sequencing data of 22 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
17 |
EGAD00001008890 |
Rare cancer sequencing data of 76 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
72 |
EGAD00001008891 |
Rare cancer sequencing data of 164 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
159 |
EGAD00001008892 |
Rare cancer sequencing data of 42 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
42 |
EGAD00001008893 |
Rare cancer sequencing data of 112 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
100 |
EGAD00001008894 |
Rare cancer sequencing data of 34 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
28 |
EGAD00001008895 |
Rare cancer sequencing data of 49 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
43 |
EGAD00001008896 |
Rare cancer sequencing data of 137 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
138 |
EGAD00001008897 |
Rare cancer sequencing data of 246 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
250 |
EGAD00001008898 |
Rare cancer sequencing data of 34 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
34 |
EGAD00001008899 |
Rare cancer sequencing data of 6 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
6 |
EGAD00001008900 |
Rare cancer sequencing data of 142 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
134 |
EGAD00001008901 |
Rare cancer sequencing data of 28 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 4000 |
24 |
EGAD00001008902 |
Rare cancer sequencing data of 85 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
77 |
EGAD00001008903 |
Rare cancer sequencing data of 36 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
34 |
EGAD00001008904 |
Rare cancer sequencing data of 112 runs in tumor/control pairs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
106 |
EGAD00001008905 |
RNA-Seq, WES and WGS data of 5 rare tumor/control pairs which were submitted to other HIPO projects, not MASTER. The sequencing was always paired. |
HiSeq X Ten,Illumina HiSeq 2000 |
11 |
EGAD00001008906 |
Part of the published data from EGAS00001004662 resulted in the publication of this study EGAS00001004813 |
HiSeq X Ten |
5 |
EGAD00001008969 |
Reads were processed with the RNA-seq workflow 1.3.0 developed by the DKFZ Omics IT and Data Management Core Facility (https://github.com/DKFZ-ODCF/RNAseqWorkflow). First, FASTQ reads were aligned via two-pass alignment using STAR 2.5.3a. The STAR index was generated from the 1000 Genomes assembly and GENCODE Version 19 gene models with a sjdbOverhang of 200. Duplicate marking of the resultant main alignment file was done with sambamba 0.6.5. Gene-specific read counting was performed using featureCounts (from Subread 1.5.1) over exon features based on GENCODE Version 19 gene models. Both reads of a paired fragment were used for counting, and the quality threshold was set to 255, indicating that STAR found a unique alignment. Strand-specific counting was also used. For RPKM and TPM calculations, all genes on chromosomes X and Y, the mitochondrial genome, as well as rRNA and tRNA genes were omitted as they are likely to introduce library size estimation biases. |
|
10 |
EGAD00001008970 |
Nanopore RNA Sequencing was done for 10 tumor samples. Direct cDNA sequencing was performed using the SQK-DCS109 kit (Oxford Nanopore Technologies). For analysis of a single sample on a MinION flow cell (version R9.4.1), 5 μg RNA was used as input. For multiplexing on a MinION flow cell, 2.5 μg RNA per sample was used as input, and the native barcoding expansion kit EXP-NBD104 was employed in conjunction with SQK-DCS109. After reverse transcription with Maxima H Minus Reverse Transcriptase (Thermo Scientific), second-strand synthesis was performed using the 2x LongAmp Taq Master Mix (New England Biolabs). The resulting double-stranded cDNA was subjected to end-repair and dA-tailing using the NEBNext Ultra End Repair/dA-Tailing Module (New England Biolabs). For multiplexed libraries, this step was followed by barcode ligation and library pooling. Next, libraries were quantified with a Qubit Fluorometer 3.0 (Life Technologies). Finally, sequencing adapters were added to the library preparations and ligated with Blunt/TA Ligase Master Mix (New England Biolabs), followed by further quality control using a Qubit. Samples ACC1 and ACC2 were analyzed on individual MinION flow cells, while the remaining eight samples were sequenced as multiplexed libraries on two MinION flow cells by pooling four samples for each run. Five ACC samples were also analyzed individually on Flongle flow cells |
MinION |
10 |
EGAD00001008971 |
Fastq files of paired RNA-Seq of 10 different tumor samples, for which Nanopore and Illumina sequencing was compared. Illumina sequencing was carried out with HiSeq4000 or HiSeq X-Ten using the Illumina TruSeq stranded mRNA Kit. |
HiSeq X Ten,Illumina HiSeq 4000 |
10 |
EGAD00001009270 |
10X Genomics scRNA- and TCR-sequencing (Chromium Next GEM Single Cell 5’
Reagent Kit v1.1) was performed on the plasma cell depleted mononuclear
fraction of bone marrow aspirates from 6 patients with newly diagnosed
multiple myeloma. Generated gene expression libraries were paired-end sequenced on the NovaSeq
6000 S2. Generated V(D)J libraries were paired-end sequenced on the NextSeq
550. |
|
12 |
EGAD00001009272 |
WES/WGS sequencing data of 234 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
233 |
EGAD00001009273 |
WES/WGS sequencing data of 86 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
86 |
EGAD00001009274 |
WES/WGS sequencing data of 337 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten,Illumina HiSeq 4000 |
319 |
EGAD00001009275 |
WES/WGS sequencing data of 56 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
56 |
EGAD00001009276 |
WES/WGS sequencing data of 75 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2000,Illumina HiSeq 2500,Illumina HiSeq 4000 |
74 |
EGAD00001009277 |
WES/WGS sequencing data of 44 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
40 |
EGAD00001009278 |
WES/WGS sequencing data of 242 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
Illumina HiSeq 2500,Illumina HiSeq 4000 |
242 |
EGAD00001009279 |
WES/WGS sequencing data of 239 chromothriptic tumor and control runs, which were uploaded to umbrella studies. The sequencing was always paired |
HiSeq X Ten |
218 |
EGAD00001009490 |
Oxford Nanopore Technologies (ONT) long-read sequencing in a paired diagnostic and post- therapy medulloblastoma (2 samples). One sequencing was done on GridION, the other one on a P2 Solo. In both cases the SQK LSK-109 Kit was used for preparation. |
GridION,PromethION |
2 |
EGAD00001009624 |
high coverage whole genome sequencing of 38 samples was done on a patterned flowcell v.2.5 (150 bp paired end, HiSeq X Ten) with coverage of about 60x for the tumor and whole blood control samples. All tumors had a tumor cell content of ≥60%. Sequencing libraries were prepared using the Truseq DNA Nano kit (Illumina) according to the manufacturers’ instructions and size selected using SPRI beads (Beckman Coulter Genomics). |
HiSeq X Ten |
18 |
EGAD00001009670 |
Sequencing data of 20 tumor runs (different tumors), which were uploaded to EGAS00001004813 and used in the ImmuNeo publication. The sequencing was always paired and run on Illumina HiSeq sequencers. |
HiSeq X Ten,Illumina HiSeq 4000 |
1 |
EGAD00001009671 |
Sequencing data of 39 tumor and control runs (different tumors and blood controls), which were uploaded to EGAS00001004813 and reused in this ImmuNEO publication. The sequencing was always paired. |
HiSeq X Ten,Illumina HiSeq 4000 |
0 |
EGAD00001009689 |
FAST5 original nanopore data from MinION sequencing of 10 tumor samples |
|
10 |
EGAD00001009690 |
Reads were aligned to 1000 Genomes assembly reference (hs37d5) using minimap2 2.22. SAM-to-BAM conversion, BAM sorting and indexing were performed with SAMtools 1.13. Read summarization was performed with featureCounts (from Subread 2.0.3) over exon features based on GENCODE Version 19 gene models. Strand specific counting was used. |
|
10 |
EGAD00001009705 |
Paired Exome sequencing of 34 samples (tumors and controls) of different tumors. The samples were prepared using Agilent SureSelect V5+UTRs, the sequencing was done on Illumina HiSeq 4000. |
Illumina HiSeq 4000 |
34 |
EGAD00001009706 |
Paired RNA sequencing data (21 runs/ 17 samples) of different tumors. The samples were prepared using the Illumina TruSeq stranded mRNA Kit. The sequencing was done on Illumina HiSeq 4000. |
Illumina HiSeq 4000 |
17 |
EGAD00001009730 |
Paired RNA-Seq of four patients with advanced Parathyroid carcinoma (PC). The library was prepared using the Illumina TruSeq stranded mRNA Kit, the sequencing was done either on an Illumina HiSeq 4000 or on Illumina NovaSeq 6000. |
Illumina HiSeq 4000,Illumina NovaSeq 6000 |
4 |
EGAD00001009731 |
Paired WGS data of four patients with advanced Parathyroid carcinoma (PC). There are tumor/control pairs (buffy coat control). The library was prepared with Illumina TruSeq Nano DNA, the sequencing was done with HiSeq X Ten. |
HiSeq X Ten |
8 |
EGAD00001010046 |
WES/WGS sequencing data of 37 germline runs, which were uploaded to umbrella studies. The sequencing was always paired. The WGS sequencing was on HiSeq X Ten using the Illumina TruSeq DNA Nano Kit. The WES Sequencing was on HiSeq4000 with Agilent Sureselect V5+UTR. |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000 |
1 |
EGAD00001010047 |
The control samples (mostly blood) of 351 samples (paired WGS and WES sequencing) are in this dataset. The WGS was in nearly all cases at an Illumina HighSeq X Ten with the Illumina TruSeq Nano DNA Kit. The WES mostly on Illumina HighSeq 4000 with the Agilent SureSelect V5 plus UTRs Kit. |
HiSeq X Ten,Illumina HiSeq 2500,Illumina HiSeq 4000,Illumina NovaSeq 6000 |
353 |
EGAD00010000947 |
Lymphoma samples using CytoSNP |
Illumina CytoSNP |
35 |
EGAD00010000948 |
Lymphoma samples using 450k |
Illumina 450k |
95 |
EGAD00010000949 |
Lymphoma samples using HumanOmni |
Illumina HumanOmni2.5 |
104 |
EGAD00010001642 |
|
Illumina EPIC methylation bead array |
25 |
EGAD00010001643 |
|
Illumina 450k methylation bead array |
73 |
EGAD00010001797 |
Methylation microarray profiling (Illumina Human Methylation 450k and EPIC platforms) of 60 adult glioblastomas. Tumours were subtyped using the approach from Sturm et al. (https://doi.org/10.1016/j.ccr.2012.08.024): 12 IDH, 18 MES, 12 RTK I, 18 RTK II. DNA was prepared, assayed on the microarrays, and raw data computationally processed as described in Capper et al., "DNA methylation-based classification of central nervous system tumours": https://www.nature.com/articles/nature26000 |
|
60 |
EGAD00010001936 |
Gene expression of 12 colon cancer TSCs (sensitive or resistant) after 12h treatment with 3µM NCT02 or DMSO (control) was analyzed using Illumina microarrays (HumanHT-12 v4 BeadChip). |
oligonucleotide beads of HumanHT-12 V4 R2 Expression BeadChips (Illumina) |
24 |
EGAD00010002004 |
PDAC primary cell lines methylation |
|
7 |
EGAD00010002005 |
PDAC PDX methylation |
|
18 |
EGAD00010002036 |
CUP samples using 850k |
Illumina 850k |
55 |